Life science companies invest billions of dollars each year researching and developing new treatments for patients. Each of these clinical studies is carefully designed to test specific hypotheses about treatment safety and efficacy, which are laid out in the study protocol. Yet for all of this investment, more than 85% of the treatments that are studied in Phase I trials never receive FDA approval.
Explore how Datavant can be your health data logistics partner.
Contact us
.svg)
